ATAI News & Events

AtaiBeckley provided clinical, regulatory, and operational milestones from its 2026 Virtual Investor Day, including the advancement of BPL-003 - mebufotenin benzoate nasal spray - toward Phase 3 initiation in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA. BPL-003, which holds Breakthrough Therapy Designation, is supported by positive Phase 2b results in treatment-resistant depression, or TRD, demonstrating rapid antidepressant effects at Day 2, durable improvements through eight weeks, and higher response and remission rates following an optional second dose in the open-label extension. The company also reaffirmed its cash runway into early 2029, provided updates on its commercial readiness strategy, and outlined continued pipeline progress, including recently announced positive Phase 2a results for EMP-01 and its expectation that VLS-01 will deliver Phase 2 topline data in H2 2026. The company outlined a scalable treatment model without requiring in-session psychotherapy, enabling clinics to incorporate BPL-003 within established care pathways.

Reports Q4 revenue $1.1M vs. ($5,000) last year. "Following our strategic combination of atai Life Sciences and Beckley Psytech, and U.S. redomiciliation, we have entered a pivotal execution phase," said Srinivas Rao, M.D., Ph.D., Chief Executive Officer and Co-Founder of AtaiBeckley. "We received constructive feedback from the FDA on the Phase 3 development plan for BPL-003 in treatment-resistant depression, positioning us to initiate our pivotal program in the second quarter of 2026. We also reported positive topline results from our exploratory Phase 2a study of EMP-01 in Social Anxiety Disorder, which met its primary safety objective and demonstrated clinically meaningful improvements across key efficacy measures after just two administrations and without adjunct psychotherapy. With multiple clinical catalysts ahead and capital expected to fund operations into 2029, we believe AtaiBeckley is well positioned to advance a differentiated portfolio of rapid-acting mental health therapies."

As of December 31, 2025, the Company had cash, cash equivalents and short-term securities of $220.7 million compared to $72.3 million of cash, cash equivalents, restricted cash and short-term securities as of December 31, 2024. The $148.4 million increase is primarily attributable to $291.1 million in net proceeds from equity-related issuances and $9.1 million in proceeds from sale of equity holdings, partially offset by $102.7 million used in operations, $21.8 million payoff of Hercules debt facility, $20.0 million in payments relating to the Beckley Psytech investment prior to the strategic combination, and $10.0 million investment in digital assets. The Company expects its cash, cash equivalents, short-term investments and other liquid assets to fund operations into 2029.